Eroom’s Law in the Pharmaceutical Industry – And How AI Can Beat It

Turning Pharma’s Billion-Dollar Failures and R&D Slumps into a Smarter, Faster Productivity Boom

1. Introduction

The pharmaceutical industry is at a precarious crossroads. While advances in genomics, computational biology, and precision medicine have transformed science, the process of developing new drugs has only grown more inefficient. Today, the industry faces a “double threat” that jeopardizes its future.

On one front is the imminent “patent cliff.” Over the coming five years, patents for many major drugs held by big pharma are set to expire, opening the door for generics to enter the market. This shift threatens to severely undercut the bottom line for major companies just as they need revenue the most.

Compounding this revenue threat is the crisis of Eroom’s Law—the observation that the cost of developing a new drug has doubled approximately every nine years since the 1950s. This phenomenon runs directly counter to Moore’s Law, which predicted exponential improvements in computing power. In fact, Eroom’s Law has become shorthand for the industry’s productivity crisis: despite bigger R&D budgets, better equipment, and larger data pools, fewer drugs make it to market per billion dollars spent.

Caught between the revenue erosion of the patent cliff and the skyrocketing costs of slow discovery pipelines, companies face high attrition and uncertain returns on investment. For society, the consequence is clear: life-saving therapies are delayed or priced beyond reach.

2. The Crisis of Eroom’s Law

Developing a single drug today has become a staggering financial gamble. According to a 2025 analysis, the average cost to bring a new asset to market rose to $2.23 billion in 2024, continuing an upward trend driven by longer cycle times and economic pressures. Despite this massive investment, the industry remains plagued by high failure rates, with over 90% of drug candidates failing in clinical trials.

This productivity crisis is now compounded by a “double threat” that puts the industry’s financial backbone at risk. Alongside the scientific stagnation of Eroom’s Law, pharma faces a super-cliff of patent expirations between 2025 and 2030. During this period, approximately 190 major medicines—including 69 blockbuster products—will lose market exclusivity, putting nearly $236 billion to $400 billion in annual revenue at risk as generics and biosimilars flood the market.

Caught between this unprecedented revenue erosion and the skyrocketing costs of discovery, the industry is in a race against time. While there have been temporary boosts to industry-wide ROI figures to 5.9% in 2024, the underlying reality is stark: without these few outliers, the return on investment for the rest of the industry drops to just 3.8%.

So, why has progress slowed?

Root Causes of Declining Productivity

• Scientific Complexity & The “Better than the Beatles” Problem
  Today’s drugs must outperform already highly effective treatments—the “Beatles” of the medical world. The bar for approval has risen significantly, as new therapies must demonstrate superiority over established standards of care to secure reimbursement. This is particularly challenging in complex fields like neurology and oncology, where “low-hanging fruit” has long been harvested, forcing researchers to target novel but unproven biological pathways.
• Regulatory Hurdles & The Inflation Reduction Act (IRA)
  Beyond standard safety requirements, new regulations are reshaping R&D incentives. The Inflation Reduction Act (IRA) has introduced a “ticking clock” for small molecule drugs, making them eligible for price negotiation just 9 years after approval (compared to 13 years for biologics). This policy shift has disproportionately disincentivized investment in small molecules, with post-approval clinical trials for these drugs dropping by 45% following the Act’s passage, as companies pivot toward biologics to protect their returns.
• Over-Reliance on Known Chemistry & Redundant Datasets
  Modern discovery suffers from a massive redundancy problem. A 2024 study highlights that despite the “billions” of compounds in virtual libraries, most research is biased toward known chemical spaces that are historically over-represented. This creates a feedback loop where AI models trained on public data merely reproduce variations of existing drugs rather than exploring the vast, uncharted chemical universe of estimated 10⁶⁰ molecules.
• ROI Constraints on Rare Diseases
  While the need for rare disease treatments is urgent, the economics are becoming increasingly difficult. BCG’s 2025 report notes that while new modalities offer hope, they face stalled growth due to high costs and limited patient populations. Furthermore, recent market analysis indicates that high development costs combined with small cohorts limit the ROI, forcing companies to prioritize “blockbuster” indications unless specific de-risking strategies are employed.
• Manufacturing & Chemical Space Limitations
  There is a widening gap between what AI can design and what labs can actually build. A 2025 industry report emphasizes that novel modalities (like antibody-drug conjugates) face significant scale-up bottlenecks, with 70-80% of developers lacking in-house capacity. We are effectively limited to a small “island” of manufacturable compounds; promising candidates that require complex synthesis or novel scaffolds are often discarded early because they cannot be produced reliably at industrial scales.
• Poor Predictive Models & The Animal Testing Gap
  Animal studies remain a major source of late-stage failure. A 2025 legal and regulatory analysis reinforces that animal models are often poor predictors of human efficacy, contributing directly to the 90% clinical failure rate. Consequently, the FDA is aggressively pivoting toward New Approach Methodologies (NAMs)—such as organ-chips and AI simulations—to replace these outdated models, though the transition remains a significant operational hurdle.

The result: an unsustainable cycle where R&D spending grows, but outputs stagnate.

3. Why Traditional Fixes Haven’t Worked

Pharma companies have tried to “throw money” at the problem with automation, robotics, and outsourcing. While these efforts bring operational efficiencies, they don’t tackle the core issue: predictability.

If a model cannot reliably predict how a drug will behave in humans, no amount of high-throughput screening or additional manpower will fix the problem. Eroom’s Law is not about speed alone—it’s about the quality of insights driving discovery.

4. How AI Can Reverse Eroom’s Law

Artificial Intelligence represents more than just another tool in pharma’s arsenal—it is a fundamental shift in how drugs are conceived, designed, and tested. Unlike brute force, AI thrives on patterns, prediction, and optimization, making it uniquely suited to tackle the root causes of Eroom’s Law.

5. EPOSMol: A Case in Point

Quantiphi’s EPOSMol framework (Evolutionary Policy Optimization for Small Molecules) exemplifies how AI can directly counter the stagnation of Eroom’s Law. By combining generative AI with evolutionary policy gradient optimization, EPOSMol doesn’t just generate random molecules—it intelligently steers discovery toward novel, diverse, and biologically promising candidates.

Unlike traditional generative models—which often produce invalid or redundant molecules—EPOSMol takes a multi-pronged, smarter approach:

• Generative AI: Learns from billions of molecules to create chemically valid, novel structures.
• Policy Gradient Reinforcement Learning: “Learns from past shots,” refining strategies after each iteration to improve outcomes.
• Evolutionary Search: Inspired by natural selection, molecules are refined across generations, selecting the best candidates at each step.
• Dynamic Scheduling: Explores broadly at first, then narrows focus on promising molecules for efficient optimization.

The results speak volumes:

• Unprecedented Hit Rates – In extended experimental runs, EPOSMol identified over 11,800 high-affinity hits, demonstrating a 10x higher hit rate compared to baseline generative models like REINVENT. This efficiency allows research teams to identify viable candidates significantly faster than traditional methods.
• Massive Chemical Exploration – The framework successfully generated 36,000+ novel compounds, effectively expanding the “search radius” for drug discovery. By exploring beyond the limitations of standard libraries, AI discovers chemical matter that human intuition might overlook.
• High-Quality Novelty – Crucially, these compounds are not just derivatives of existing drugs. EPOSMol produced hundreds of unique scaffolds, ensuring high structural diversity and strong patent potential for the resulting assets.
• Feasible Innovation (Potency + Manufacturability) – The identified molecules exhibit binding affinities in the nanomolar range while maintaining very low synthetic accessibility (SA) scores. This combination indicates that the system produces potent binders that are easy to manufacture and test, solving the critical “scale-up” bottleneck often seen in AI drug design.

Crucially, EPOSMol delivers optimized novelty—molecules that are not only new but tailored for drug-likeness, structural diversity, and target-specific objectives.

While EPOSMol is just one example, it clearly demonstrates how AI-driven molecular engineering can deliver tangible improvements in speed, diversity, and success rates—the very metrics where Eroom’s Law has historically held pharma back.

This intelligent, multi-dimensional exploration offers a practical blueprint for smarter drug discovery, providing the pharma industry a path to overcome stagnation and unlock the next generation of therapeutics.

6. Challenges on the Road to Reversal

AI is not a magic wand. To fully overcome Eroom’s Law, the industry must address:

• Data quality and standardization: AI is only as good as the data it learns from. Inconsistent or biased datasets undermine predictive accuracy.
• Regulatory acceptance: Authorities must evolve to validate AI-generated insights and adaptive trial designs.
• Organizational inertia: Pharma is conservative; cultural and structural shifts are necessary to integrate AI deeply into workflows.

Still, the trajectory is clear: AI is not just another efficiency booster—it is the strategic weapon pharma needs to restore productivity.

7. The Road Ahead Beyond Eroom’s Law

Eroom’s Law has long symbolized the decline of pharmaceutical R&D productivity. The stakes are enormous: higher drug costs, fewer breakthroughs, and delayed therapies for patients in need. But AI offers a real chance to rewrite this story.

By making discovery smarter, predictions more accurate, and clinical trials more efficient, AI has the power to bend the curve of Eroom’s Law. The question is no longer if AI can make an impact—but how fast the industry will embrace it.

EPOSMol is just the beginning. At Quantiphi, we are moving beyond isolated point solutions to build a comprehensive, AI-first drug discovery ecosystem. We are actively developing a unified Drug Discovery and Target Validation Suite—a platform designed to break down silos and connect the dots between biology and chemistry. While this fully integrated suite is currently in development and set to launch in the coming months, our proven capabilities already span the entire R&D lifecycle:

• Target Identification: We leverage “deep research” agents and Knowledge Graphs to validate previously undruggable targets from millions of data points.
• Generative Chemistry: Beyond screening, we use molecular engineering to design novel, patentable scaffolds that balance potency with manufacturability.
• Predictive Modeling: Our DART platform utilizes human-relevant data to simulate toxicity and efficacy, helping teams fail fast and cheap in silico rather than in the clinic.

With 2,500+ AI projects delivered and a dedicated team of 300+ healthcare and life sciences experts, we bring AI-first solutions like EPOSMol to accelerate discovery, optimize pipelines, and reduce time-to-market—building the digital infrastructure that will allow the industry to finally break the curse of Eroom’s Law.

Ready to transform your R&D pipeline with AI? Connect with Quantiphi’s experts today and take the first step toward reversing Eroom’s Law.

FAQs